- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 548498, 12 pages
A Systems Biology-Based Investigation into the Pharmacological Mechanisms of Wu Tou Tang Acting on Rheumatoid Arthritis by Integrating Network Analysis
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nanxiaojie, Dongzhimennei, Beijing 100700, China
Received 11 January 2013; Accepted 20 February 2013
Academic Editor: Aiping Lu
Copyright © 2013 Yanqiong Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Table S1: describes the detailed information on known drugs and therapeutic targets for the treatment of rheumatoid arthritis. It includes drug name, drug accession number, drug group, target name, target UniprotID and target gene symbol.
Table S2: describes the detailed information on eight existing protein-protein interaction databases including source name, website and release number/last updated date.
Table S3: describes the detailed information on the similar drugs of compositive compounds of each ingredient in Wu Tou Tang and the predicted effector molecules of Wu Tou Tang.
Table S4: describes the detailed information on the FDA-approved drugs for the treatment of rheumatoid arthritis and their known targets.
Table S5: describes the detailed information on the major candidate effector molecules and their corresponding compounds in Wu Tou Tang including drug compounds, drug target UniprotID, drug target UniprotACC and drug target gene symbol.
Table S6: describes the detailed information on the positive docking results for compound-potential target interactions including drug compound, drug target UniprotID, drug target UniprotACC, drug target gene symbol, drug target PDB ID and Ehits score.